Skip to main content
. 2024 Nov 1;13(21):e70308. doi: 10.1002/cam4.70308

FIGURE 2.

FIGURE 2

Sample selection. (1) Exclusion criteria were not mutually exclusive. DRd, daratumumab, lenalidomide, and dexamethasone; FL, front‐line; ICD‐10 CM, International Classification of Disease, 10th Revision, Clinical Modification; IPTW, inverse probability of treatment weighting; MM, multiple myeloma; VRd, bortezomib, lenalidomide, and dexamethasone.